Breast Cancer Survival Breakthrough: New AI Blood Test Predicts Recurrence 5 Years Early, Reshaping Global Oncology Markets. A revolutionary liquid biopsy platform using machine learning identifies microscopic tumor DNA fragments, enabling preemptive treatment shifts that slash recurrence rates by 70%. Industry analysts predict a $2.3B market disruption as insurers rush to cover the $500 test, while Big Pharma accelerates targeted therapy development for high-risk patients identified years earlier.